Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: Implication for maintenance therapy with glycolysis inhibitors

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8703-8715

  Alvero, Ayesha B ^a   Montagna, Michele K ^a   Sumi, Natalia J ^a   Joo, Won Duk ^a   Graham, Emma ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Maintenance treatment; Ovarian cancer; Oxidative phosphorylation; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 4; DEOXYGLUCOSE; PACLITAXEL; PROSTAGLANDIN SYNTHASE; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; ANTINEOPLASTIC AGENT; CD44 PROTEIN, HUMAN; HERMES ANTIGEN; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; MULTIENZYME COMPLEX; MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; UPREGULATION; XENOGRAFT; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; MAINTENANCE CHEMOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYGLUCOSE; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; FEMALE; GLYCOLYSIS; HUMANS; I-KAPPA B KINASE; MAINTENANCE CHEMOTHERAPY; MICE; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; OXIDATIVE PHOSPHORYLATION; PACLITAXEL; PHENOTYPE; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908005580     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2367     Document Type: Article

References (50)

1. Rooth C. Ovarian cancer: risk factors, treatment and management. British journal of nursing. 2013; 22(17):S23-30.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29.
3. Wright JD, Neugut AI, Lewin SN, Lu YS, Herzog TJ and Hershman DL. Trends in hospital volume and patterns of referral for women with gynecologic cancers. Obstetrics and gynecology. 2013; 121(6):1217-1225.
4. Jelovac D and Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011; 61(3):183-203.
5. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M and Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecologic oncology. 2002; 85(1):71-80.
6. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 2003; 95(17):1320-1329.
7. Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995; 22(6 Suppl 15):1-6.
8. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-9344.
9. Clarke MF and Fuller M. Stem cells and cancer: two faces of eve. Cell. 2006; 124(6):1111-1115.
10. Dalerba P, Cho RW and Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007; 58:267-284.
11. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-284.
12. Giuffrida D and Rogers IM. Targeting cancer stem cell lines as a new treatment of human cancer. Recent patents on anticancer drug discovery. 2010; 5(3):205-218.
13. Hemmings C. The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology. 2010; 42(2):105-112.
14. Huang EH, Heidt DG, Li CW and Simeone DM. Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery. 2007; 141(4):415-419.
15. Nie D. Cancer stem cell and niche. Frontiers in bioscience. 2010; 2:184-193.
16. Sell S. On the stem cell origin of cancer. The American journal of pathology. 2010; 176(6):2584-2494.
17. Winquist RJ, Furey BF and Boucher DM. Cancer stem cells as the relevant biomass for drug discovery. Current opinion in pharmacology. 2010; 10(4):385-390.
18. Reya T, Morrison SJ, Clarke MF and Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-111.
19. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH and Lu B. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011; 2011:941876.
20. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I and Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009; 8(1):158-166.
21. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D and Mor G. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 10(8):1385-1393.
22. Bapat SA. Human ovarian cancer stem cells. Reproduction. 2010; 140(1):33-41.
23. Casagrande F, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Arin-Silasi D, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE and Santin AD. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer. 2011; 117(24):5519-5528.
24. Chefetz I, Holmberg JC, Alvero AB, Visintin I and Mor G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFkB pathway. Cell Cycle. 10(13):2206-2214.
25. Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T, Yin G, Rimm DL, Holmberg J, Alvero A and Silasi DA. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci. 2013; 20(5):605-615.
26. Steffensen KD, Alvero AB, Yang Y, Waldstrom M, Hui P, Holmberg JC, Silasi DA, Jakobsen A, Rutherford T and Mor G. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J Oncol. 2011:620523.
27. Warburg O. On respiratory impairment in cancer cells. Science. 1956; 124(3215):269-270.
28. Warburg O, Wind F and Negelein E. The Metabolism of Tumors in the Body. The Journal of general physiology. 1927; 8(6):519-530.
29. Gatenby RA and Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4(11):891-899.
30. Jose C, Bellance N and Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochimica et biophysica acta. 2011; 1807(6):552-561.
31. Riganti C, Gazzano E, Polimeni M, Aldieri E and Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med. 2012; 53(3):421-436.
32. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Progress in experimental tumor research. 1978; 22:190-274.
33. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T and Mor G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene. 2008; 27(34):4712-4723.
34. Leizer AL, Alvero AB, Fu HH, Holmberg JC, Cheng YC, Silasi DA, Rutherford T and Mor G. Regulation of inflammation by the NF-kappaB pathway in ovarian cancer stem cells. Am J Reprod Immunol. 65(4):438-447.
35. Mauro C, Leow SC, Anso E, Rocha S, Thotakura AK, Tornatore L, Moretti M, De Smaele E, Beg AA, Tergaonkar V, Chandel NS and Franzoso G. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nature cell biology. 2011; 13(10):1272-1279.
36. Johnson RF and Perkins ND. Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends in biochemical sciences. 2012; 37(8):317-324.
37. Johnson RF, Witzel, II and Perkins ND. p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB. Cancer Res. 2011; 71(16):5588-5597.
38. Craveiro V, Yang-Hartwich, Y., Holmberg, J., Sumi, N., Pizzonia, J., Griffin, B., Gill, S., Silasi, D., Azodi, M., Rutherford, T., Alvero, A.B., Mor, G. Phenotypic Modifications in Ovarian Cancer Stem Cells Following Paclitaxel Treatment. Cancer Medicine. 2013.
39. Yin G, Alvero AB, Craveiro V, Holmberg JC, Fu HH, Montagna MK, Yang Y, Chefetz-Menaker I, Nuti S, Rossi M, Silasi DA, Rutherford T and Mor G. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 2013; 32(1):39-49.
40. Reitzer LJ, Wice BM and Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979; 254(8):2669-2676.
41. Rodriguez-Enriquez S, Carreno-Fuentes L, Gallardo-Perez JC, Saavedra E, Quezada H, Vega A, Marin-Hernandez A, Olin-Sandoval V, Torres-Marquez ME and Moreno-Sanchez R. Oxidative phosphorylation is impaired by prolonged hypoxia in breast and possibly in cervix carcinoma. The international journal of biochemistry & cell biology. 2010; 42(10):1744-1751.
42. Bellance N, Benard G, Furt F, Begueret H, Smolkova K, Passerieux E, Delage JP, Baste JM, Moreau P and Rossignol R. Bioenergetics of lung tumors: alteration of mitochondrial biogenesis and respiratory capacity. The international journal of biochemistry & cell biology. 2009; 41(12):2566-2577.
43. Smolkova K, Plecita-Hlavata L, Bellance N, Benard G, Rossignol R and Jezek P. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. The international journal of biochemistry & cell biology. 2011; 43(7):950-968.
44. Sayeed A, Meng Z, Luciani G, Chen LC, Bennington JL and Dairkee SH. Negative regulation of UCP2 by TGFbeta signaling characterizes low and intermediate-grade primary breast cancer. Cell death & disease. 2010; 1:e53.
45. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, Oidtman J, Silasi DA and Mor G. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells. 2009; 27(10):2405-2413.
46. Alvero AB, Montagna MK, Chen R, Kim KH, Kyungjin K, Visintin I, Fu HH, Brown D and Mor G. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer. 2009.
47. Alvero AB, Montagna MK, Craveiro V, Liu L and Mor G. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol. 67(3):256-265.
48. Chefetz I, Alvero AB, Holmberg JC, Lebowitz N, Craveiro V, Yang-Hartwich Y, Yin G, Squillace L, Gurrea Soteras M, Aldo P and Mor G. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence. Cell Cycle. 2013; 12(3):511-521.
49. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, Rutherford T and Mor G. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer. 2006; 106(3):599-608.
50. Pizzonia J, Holmberg J, Orton S, Alvero A, Viteri O, McLaughlin W, Feke G and Mor G. Multimodality animal rotation imaging system (Mars) for in vivo detection of intraperitoneal tumors. Am J Reprod Immunol. 2012; 67(1):84-90.